Vaccine approaches conferring cross-protection against influenza viruses

References

• World Health Organization.  WHO | Influenza (Seasonal) 2017. In: WHO (Ed.^(Eds)). Available from: http://www.who.int/mediacentre/factsheets/fs211/en/
   Google Scholar
• Thompson MG, Li DK, Shifflett P, et al. Effectiveness of seasonal trivalent influenza vaccine for preventing influenza virus illness among pregnant women: a population-based case-control study during the 2010-2011 and 2011-2012 influenza seasons. Clin Infect Dis. 2014;58(4):449–457.
   PubMed Web of Science ®Google Scholar
• Thompson WW, Moore MR, Weintraub E, et al. Estimating influenza-associated deaths in the United States. Am J Public Health. 2009;99(Suppl 2):S225–230.
   PubMed Web of Science ®Google Scholar
• Thompson WW, Weintraub E, Dhankhar P, et al. Estimates of US influenza-associated deaths made using four different methods. Influenza Other Respir Viruses. 2009;3(1):37–49.
   PubMed Web of Science ®Google Scholar
• FAO H7N9 situation update - Avian Influenza A(H7N9) virus - FAO Emergency Prevention System for Animal Health (EMPRES-AH) 2017. (Ed.^(Eds)). Available from:  http://www.fao.org/ag/againfo/programmes/en/empres/h7n9/situation_update.html
   Google Scholar
• Tumpey TM, Garcia-Sastre A, Taubenberger JK, et al. Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J Virol. 2005;79(23):14933–14944.
   PubMed Web of Science ®Google Scholar
• Tumpey TM, Basler CF, Aguilar PV, et al. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science. 2005;310(5745):77–80.
   PubMed Web of Science ®Google Scholar
• Wang TT, Palese P. Unraveling the mystery of swine influenza virus. Cell. 2009;137(6):983–985.
   PubMed Web of Science ®Google Scholar
• Nichol KL, Treanor JJ. Vaccines for seasonal and pandemic influenza. J Infect Dis. 2006;194 Suppl 2:S111–118.
   PubMed Web of Science ®Google Scholar
• Manini I, Domnich A, Amicizia D, et al. Flucelvax (Optaflu) for seasonal influenza. Expert Rev Vaccines. 2015;14(6):789–804.
   PubMed Web of Science ®Google Scholar
• Montomoli E, Khadang B, Piccirella S, et al. Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production. Expert Rev Vaccines. 2012;11(5):587–594.
   PubMed Web of Science ®Google Scholar
• Izikson R, Leffell DJ, Bock SA, et al. Randomized comparison of the safety of Flublok ® versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥50 years of age. Vaccine. 2015;33(48):6622–6628.
   PubMed Web of Science ®Google Scholar
• Cox MM, Izikson R, Post P, et al. Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults. Ther Advances Vaccines. 2015;3(4):97–108.
   PubMedGoogle Scholar
• Jin H, Subbarao K. Live attenuated influenza vaccine. Curr Top Microbiol Immunol. 2015;386:181–204.
   PubMed Web of Science ®Google Scholar
• DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine. 2012;31(1):49–57.
   PubMed Web of Science ®Google Scholar
• Lang PO, Mendes A, Socquet J, et al. Effectiveness of influenza vaccine in aging and older adults: comprehensive analysis of the evidence. Clin Interv Aging. 2012;7:55–64.
   PubMed Web of Science ®Google Scholar
• Ridenhour BJ, Campitelli MA, Kwong JC, et al. Effectiveness of inactivated influenza vaccines in preventing influenza-associated deaths and hospitalizations among Ontario residents aged ≥ 65 years: estimates with generalized linear models accounting for healthy vaccine effects. PLoS One. 2013;8(10):e76318.
   PubMed Web of Science ®Google Scholar
• Nichol KL, Nordin JD, Nelson DB, et al. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med. 2007;357(14):1373–1381.
   PubMed Web of Science ®Google Scholar
• Wang TT, Tan GS, Hai R, et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A. 2010;107(44):18979–18984.
   PubMed Web of Science ®Google Scholar
• Janulikova J, Stanekova Z, Mucha V, et al. Two distinct regions of HA2 glycopolypeptide of influenza virus hemagglutinin elicit cross-protective immunity against influenza. Acta Virol. 2012;56(3):169–176.
   PubMed Web of Science ®Google Scholar
• Slepushkin VA, Katz JM, Black RA, et al. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine. 1995;13(15):1399–1402.
   PubMed Web of Science ®Google Scholar
• Frace AM, Klimov AI, Rowe T, et al. Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine. 1999;17(18):2237–2244.
   PubMed Web of Science ®Google Scholar
• Tompkins SM, Zhao ZS, Lo CY, et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis. 2007;13(3):426–435.
   PubMed Web of Science ®Google Scholar
• Park KS, Seo YB, Lee JY, et al. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e. Vaccine. 2011;29(33):5481–5487.
   PubMed Web of Science ®Google Scholar
• Zhou D, Wu TL, Lasaro MO, et al. A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge. Mol Ther. 2010;18(12):2182–2189.
   PubMed Web of Science ®Google Scholar
• Gao X, Wang W, Li Y, et al. Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge. Antiviral Res. 2013;98(1):4–11.
   PubMed Web of Science ®Google Scholar
• Wraith DC, Vessey AE, Askonas BA. Purified influenza virus nucleoprotein protects mice from lethal infection. J Gen Virol. 1987;68(Pt 2):433–440.
   PubMed Web of Science ®Google Scholar
• Donnelly JJ, Friedman A, Ulmer JB, et al. Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Vaccine. 1997;15(8):865–868.
   PubMed Web of Science ®Google Scholar
• Epstein SL, Tumpey TM, Misplon JA, et al. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis. 2002;8(8):796–801.
   PubMed Web of Science ®Google Scholar
• Wohlbold TJ, Nachbagauer R, Margine I, et al. Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses. Vaccine. 2015;33(29):3314–3321.
   PubMed Web of Science ®Google Scholar
• Epstein SL, Kong WP, Misplon JA, et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine. 2005;23(46–47):5404–5410.
   PubMed Web of Science ®Google Scholar
• Roy S, Kobinger GP, Lin J, et al. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine. 2007;25(39–40):6845–6851.
   PubMed Web of Science ®Google Scholar
• Price GE, Lo CY, Misplon JA, et al. Mucosal immunization with a candidate universal influenza vaccine reduces virus transmission in a mouse model. J Virol. 2014;88(11):6019–6030.
   PubMed Web of Science ®Google Scholar
• Florek NW, Weinfurter JT, Jegaskanda S, et al. Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques. J Virol. 2014;88(22):13418–13428.
   PubMed Web of Science ®Google Scholar
• Brewoo JN, Powell TD, Jones JC, et al. Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice. Vaccine. 2013;31(14):1848–1855.
   PubMed Web of Science ®Google Scholar
• Li Z, Gabbard JD, Mooney A, et al. Single-dose vaccination of a recombinant parainfluenza virus 5 expressing NP from H5N1 virus provides broad immunity against influenza A viruses. J Virol. 2013;87(10):5985–5993.
   PubMed Web of Science ®Google Scholar
• Li Z, Mooney AJ, Gabbard JD, et al. Recombinant parainfluenza virus 5 expressing hemagglutinin of influenza A virus H5N1 protected mice against lethal highly pathogenic avian influenza virus H5N1 challenge. J Virol. 2013;87(1):354–362.
   PubMed Web of Science ®Google Scholar
• Chen Y, Qin K, Wu WL, et al. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes. J Infect Dis. 2009;199(1):49–58.
   PubMed Web of Science ®Google Scholar
• Nabel GJ, Fauci AS. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med. 2010;16(12):1389–1391.
   PubMed Web of Science ®Google Scholar
• Pushko P, Pearce MB, Ahmad A, et al. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine. 2011;29(35):5911–5918.
   PubMed Web of Science ®Google Scholar
• Pica N, Hai R, Krammer F, et al. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A. 2012;109(7):2573–2578.
   PubMed Web of Science ®Google Scholar
• Sui J, Sheehan J, Hwang WC, et al. Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis. 2011;52(8):1003–1009.
   PubMed Web of Science ®Google Scholar
• Wang TT, Tan GS, Hai R, et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog. 2010;6(2):e1000796.
   PubMed Web of Science ®Google Scholar
• Shembekar N, Mallajosyula VV, Malik A, et al. Neutralization and binding profile of monoclonal antibodies generated against influenza A H1N1 Viruses. Monoclon Antib Immunodiagn Immunother. 2016;35(4):191–198.
   PubMedGoogle Scholar
• Malik A, Mallajosyula VV, Mishra NN, et al. Generation and characterization of monoclonal antibodies specific to avian influenza H5N1 hemagglutinin protein. Monoclon Antib Immunodiagn Immunother. 2015;34(6):436–441.
   PubMedGoogle Scholar
• Mallajosyula VV, Citron M, Lu X, et al. In vitro and in vivo characterization of designed immunogens derived from the CD-helix of the stem of influenza hemagglutinin. Proteins. 2013;81(10):1759–1775.
   PubMed Web of Science ®Google Scholar
• Shembekar N, Mallajosyula VV, Mishra A, et al. Isolation of a high affinity neutralizing monoclonal antibody against 2009 pandemic H1N1 virus that binds at the ‘Sa’ antigenic site. PLoS One. 2013;8(1):e55516.
   PubMed Web of Science ®Google Scholar
• Tan GS, Krammer F, Eggink D, et al. A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J Virol. 2012;86(11):6179–6188.
   PubMed Web of Science ®Google Scholar
• Andrews SF, Huang Y, Kaur K, et al. Immune history profoundly affects broadly protective B cell responses to influenza. Sci Transl Med. 2015;7(316):316ra192.
   PubMed Web of Science ®Google Scholar
• Valkenburg SA, Mallajosyula VV, Li OT, et al. Stalking influenza by vaccination with pre-fusion headless HA mini-stem. Sci Rep. 2016;6:22666.
   PubMed Web of Science ®Google Scholar
• Mallajosyula VV, Citron M, Ferrara F, et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc Natl Acad Sci U S A. 2014;111(25):E2514–2523.
   PubMed Web of Science ®Google Scholar
• Gong X, Yin H, Shi Y, et al. Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B. Emerg Microbes Infect. 2016;5:e51.
   PubMed Web of Science ®Google Scholar
• Vemula SV, Ahi YS, Swaim AM, et al. Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness. PLoS One. 2013;8(4):e62496.
   PubMed Web of Science ®Google Scholar
• Kamlangdee A, Kingstad-Bakke B, Osorio JE. Mosaic H5 hemagglutinin provides broad humoral and cellular immune responses against influenza viruses. J Virol. 2016;90(15):6771–6783.
   PubMed Web of Science ®Google Scholar
• Kamlangdee A, Kingstad-Bakke B, Anderson TK, et al. Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene. J Virol. 2014;88(22):13300–13309.
   PubMed Web of Science ®Google Scholar
• Impagliazzo A, Milder F, Kuipers H, et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science. 2015;349(6254):1301–1306.
   PubMed Web of Science ®Google Scholar
• Yassine HM, Boyington JC, McTamney PM, et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med. 2015;21(9):1065–1070.
   PubMed Web of Science ®Google Scholar
• Ermler ME, Kirkpatrick E, Sun W, et al. Chimeric hemagglutinin constructs induce broad protection against influenza b virus challenge in the mouse model. J Virol. 2017;91:12.
   Web of Science ®Google Scholar
• Deng L, Cho KJ, Fiers W, et al. M2e-Based universal influenza a vaccines. Vaccines (Basel). 2015;3(1):105–136.
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Tierney EL, Zebedee SL, et al. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol. 1990;64(3):1375–1377.
   PubMed Web of Science ®Google Scholar
• Zebedee SL, Lamb RA. Growth restriction of influenza A virus by M2 protein antibody is genetically linked to the M1 protein. Proc Natl Acad Sci U S A. 1989;86(3):1061–1065.
   PubMed Web of Science ®Google Scholar
• Deng L, Ibanez LI, Van den Bossche V, et al. Protection against influenza a virus challenge with M2e-Displaying filamentous escherichia coli phages. PLoS One. 2015;10(5):e0126650.
   PubMed Web of Science ®Google Scholar
• El Bakkouri K, Descamps F, De Filette M, et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: fc receptors and alveolar macrophages mediate protection. J Immunol. 2011;186(2):1022–1031.
   PubMed Web of Science ®Google Scholar
• Portela A, Digard P. The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication. J Gen Virol. 2002;83(Pt 4):723–734.
   PubMed Web of Science ®Google Scholar
• Lamere MW, Moquin A, Lee FE, et al. Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J Virol. 2011;85(10):5027–5035.
   PubMed Web of Science ®Google Scholar
• LaMere MW, Lam HT, Moquin A, et al. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol. 2011;186(7):4331–4339.
   PubMed Web of Science ®Google Scholar
• Yewdell JW, Bennink JR, Smith GL, et al. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A. 1985;82(6):1785–1789.
   PubMed Web of Science ®Google Scholar
• Townsend AR, Skehel JJ, Taylor PM, et al. Recognition of influenza A virus nucleoprotein by an H-2-restricted cytotoxic T-cell clone. Virology. 1984;133(2):456–459.
   PubMed Web of Science ®Google Scholar
• Wraith DC, Askonas BA. Induction of influenza A virus cross-reactive cytotoxic T cells by a nucleoprotein/haemagglutinin preparation. J Gen Virol. 1985;66(Pt 6):1327–1331.
   PubMed Web of Science ®Google Scholar
• Hoelscher MA, Singh N, Garg S, et al. A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses. J Infect Dis. 2008;197(8):1185–1188.
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim JY, Choi Y, et al. Mucosal vaccination with recombinant adenovirus encoding nucleoprotein provides potent protection against influenza virus infection. PLoS One. 2013;8(9):e75460.
   PubMed Web of Science ®Google Scholar
• Vitelli A, Quirion MR, Lo CY, et al. Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus. PLoS One. 2013;8(3):e55435.
   PubMed Web of Science ®Google Scholar
• Berthoud TK, Hamill M, Lillie PJ, et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis. 2011;52(1):1–7.
   PubMed Web of Science ®Google Scholar
• Antrobus RD, Lillie PJ, Berthoud TK, et al. A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. PLoS One. 2012;7(10):e48322.
   PubMed Web of Science ®Google Scholar
• Antrobus RD, Berthoud TK, Mullarkey CE, et al. Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses. Mol Ther. 2014;22(1):233–238.
   PubMed Web of Science ®Google Scholar
• Powell TJ, Peng Y, Berthoud TK, et al. Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine. PLoS One. 2013;8(5):e62778.
   PubMed Web of Science ®Google Scholar
• Lillie PJ, Berthoud TK, Powell TJ, et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis. 2012;55(1):19–25.
   PubMed Web of Science ®Google Scholar
• Morrey JD, Motter NE, Chang S, et al. Breaking B and T cell tolerance using cationic lipid–DNA complexes (CLDC) as a vaccine adjuvant with hepatitis B virus (HBV) surface antigen in transgenic mice expressing HBV. Antiviral Res. 2011;90(3):227–230.
   PubMed Web of Science ®Google Scholar
• Holman DH, Wang D, Raja NU, et al. Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses. Vaccine. 2008;26(21):2627–2639.
   PubMed Web of Science ®Google Scholar
• Fries LF, Smith GE, Glenn GM. A recombinant viruslike particle influenza A (H7N9) vaccine. N Engl J Med. 2013;369(26):2564–2566.
   PubMed Web of Science ®Google Scholar
• Music N, Reber AJ, Kim MC, et al. Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets. Vaccine. 2016;34(4):466–473.
   PubMed Web of Science ®Google Scholar
• Song BM, Kang HM, Lee EK, et al. Supplemented vaccination with tandem repeat M2e virus-like particles enhances protection against homologous and heterologous HPAI H5 viruses in chickens. Vaccine. 2016;34(5):678–686.
   PubMed Web of Science ®Google Scholar
• Ross TM, Mahmood K, Crevar CJ, et al. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS One. 2009;4(6):e6032.
   PubMed Web of Science ®Google Scholar
• Guy B, Pascal N, Francon A, et al. Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine. 2001;19(13–14):1794–1805.
   PubMed Web of Science ®Google Scholar
• Song JM, Van Rooijen N, Bozja J, et al. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci U S A. 2011;108(2):757–761.
   PubMed Web of Science ®Google Scholar
• Low JG, Lee LS, Ooi EE, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers. Vaccine. 2014;32(39):5041–5048.
   PubMed Web of Science ®Google Scholar
• Valero-Pacheco N, Perez-Toledo M, Villasis-Keever MA, et al. Antibody persistence in adults two years after vaccination with an H1N1 2009 pandemic influenza virus-like particle vaccine. PLoS One. 2016;11(2):e0150146.
   PubMed Web of Science ®Google Scholar
• Sambhara S, Kurichh A, Miranda R, et al. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell Immunol. 2001;211(2):143–153.
   PubMed Web of Science ®Google Scholar
• Sambhara S, Woods S, Arpino R, et al. Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes. J Infect Dis. 1998;177(5):1266–1274.
   PubMed Web of Science ®Google Scholar
• Dong L, Liu F, Fairman J, et al. Cationic liposome-DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice. Vaccine. 2012;30(2):254–264.
   PubMed Web of Science ®Google Scholar
• Bihari I, Panczel G, Kovacs J, et al. Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects. Clin Vaccine Immunol. 2012;19(12):1943–1948.
   PubMed Web of Science ®Google Scholar
• Rimmelzwaan GF, Nieuwkoop N, Brandenburg A, et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine. 2000;19(9–10):1180–1187.
   PubMed Web of Science ®Google Scholar
• Carmona A, Omenaca F, Tejedor JC, et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine. 2010;28(36):5837–5844.
   PubMed Web of Science ®Google Scholar
• Quan FS, Compans RW, Nguyen HH, et al. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol. 2008;82(3):1350–1359.
   PubMed Web of Science ®Google Scholar
• Dormitzer PR, Tsai TF, Del Giudice G. New technologies for influenza vaccines. Hum Vaccin Immunother. 2012;8(1):45–58.
   PubMed Web of Science ®Google Scholar
• Lay M, Callejo B, Chang S, et al. Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine. 2009;27(29):3811–3820.
   PubMed Web of Science ®Google Scholar
• Morrey JD, Motter NE, Taro B, et al. Efficacy of cationic lipid-DNA complexes (CLDC) on hepatitis B virus in transgenic mice. Antiviral Res. 2008;79(1):71–79.
   PubMed Web of Science ®Google Scholar
• Garcia-Sicilia J, Aristegui J, Omenaca F, et al. Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: two open, uncontrolled studies. Hum Vaccin Immunother. 2015;11(10):2359–2369.
   PubMed Web of Science ®Google Scholar
• Launay O, Desaint C, Durier C, et al. Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J Infect Dis. 2011;204(1):124–134.
   PubMed Web of Science ®Google Scholar
• Roman F, Vaman T, Gerlach B, et al. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine. 2010;28(7):1740–1745.
   PubMed Web of Science ®Google Scholar
• Risi G, Frenette L, Langley JM, et al. Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 months. Vaccine. 2013;31(2):436–437.
   PubMed Web of Science ®Google Scholar
• Langley JM, Vanderkooi OG, Garfield HA, et al. Immunogenicity and safety of 2 dose levels of a thimerosal-free trivalent seasonal influenza vaccine in children aged 6–35 months: a randomized, controlled trial. J Pediatric Infect Dis Soc. 2012;55–63.
   PubMedGoogle Scholar
• Langley JM, Risi G, Caldwell M, et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis. 2011;203(12):1729–1738.
   PubMed Web of Science ®Google Scholar
• Risi G, Frenette L, Langley JM, et al. Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 months. Vaccine. 2011;29(37):6408–6418.
   PubMed Web of Science ®Google Scholar
• Langley JM, Frenette L, Ferguson L, et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis. 2010;201(11):1644–1653.
   PubMed Web of Science ®Google Scholar
• Langley JM, Halperin SA, McNeil S, et al. Safety and immunogenicity of a Proteosome -trivalent inactivated influenza vaccine, given nasally to healthy adults. Vaccine. 2006;24(10):1601–1608.
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Devaster JM, Leroux-Roels G, et al. Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials. Vaccine. 2015;33(4):577–584.
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Beran J, Devaster JM, et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis. 2013;13(6):485–496.
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet. 2007;370(9587):580–589.
   PubMed Web of Science ®Google Scholar
• Cao W, Davis WG, Kim JH, et al. An oil-in-water nanoemulsion enhances immunogenicity of H5N1 vaccine in mice. Nanomedicine. 2016;12(7):1909–1917.
   PubMed Web of Science ®Google Scholar
• Chen MW, Cheng TJ, Huang Y, et al. A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci U S A. 2008;105(36):13538–13543.
   PubMed Web of Science ®Google Scholar
• Weaver EA, Rubrum AM, Webby RJ, et al. Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin. PLoS One. 2011;6(3):e18314.
   PubMed Web of Science ®Google Scholar
• Laddy DJ, Yan J, Kutzler M, et al. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS One. 2008;3(6):e2517.
   PubMed Web of Science ®Google Scholar
• Giles BM, Crevar CJ, Carter DM, et al. A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection. J Infect Dis. 2012;205(10):1562–1570.
   PubMed Web of Science ®Google Scholar
• Giles BM, Bissel SJ, Dealmeida DR, et al. Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines. Clin Vaccine Immunol. 2012;19(2):128–139.
   PubMed Web of Science ®Google Scholar
• Ekiert DC, Kashyap AK, Steel J, et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature. 2012;489(7417):526–532.
   PubMed Web of Science ®Google Scholar
• Ekiert DC, Wilson IA. Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. Curr Opin Virol. 2012;2(2):134–141.
   PubMed Web of Science ®Google Scholar
• Ekiert DC, Friesen RH, Bhabha G, et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science. 2011;333(6044):843–850.
   PubMed Web of Science ®Google Scholar
• Ekiert DC, Bhabha G, Elsliger MA, et al. Antibody recognition of a highly conserved influenza virus epitope. Science. 2009;324(5924):246–251.
   PubMed Web of Science ®Google Scholar
• Corti D, Voss J, Gamblin SJ, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333(6044):850–856.
   PubMed Web of Science ®Google Scholar
• Joyce MG, Wheatley AK, Thomas PV, et al. Vaccine-induced antibodies that neutralize group 1 and group 2 influenza a viruses. Cell. 2016;166(3):609–623.
   PubMed Web of Science ®Google Scholar
• Nachbagauer R, Krammer F. Universal influenza virus vaccines and therapeutic antibodies. Clin Microbiol Infect. 2017;23(4):222–228.
   PubMed Web of Science ®Google Scholar